Showing 211-220 of 354 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Pseudohypoxia to improve SC-beta engraftment | The Regents of the University of California, San Francisco | Qizhi Tang | Cures | 01-October-2025 to 30-September-2027 | $600,000.00 |
| Mechanisms of parathyroid protection of transplanted islets | The Regents of the University of California, San Francisco | Peng Xiao | Cures | 01-March-2024 to 28-February-2027 | $228,995.00 |
| Designing a safe and effective strategy for T1D cell replacement therapy | The Regents of the University of California, San Francisco | Nur Shabrina Amirruddin | Cures | 01-March-2025 to 29-February-2028 | $264,895.00 |
| Assessing Beta Cell Fragility in STAT1 Gain-of-Function Diabetes | The Regents of the University of California, San Francisco | Martin Thelin | Cures | 01-July-2026 to 30-June-2027 | $50,000.00 |
| Generation of vascularized, transplantable islets from human iPSC-derived beta and isogenic vasculogenic cells | The Regents of the University of California, San Francisco | Julie Sneddon | Cures | 01-July-2024 to 30-June-2026 | $599,999.99 |
| Mesh Oxygen Transporter for improved engraftment of human stem cell-derived pancreatic islet cells in the subcutaneous site | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 30-June-2027 | $294,796.07 |
| Sequential multi-molecule release from nanofiber scaffolds for improved stem cell-derived islet transplantation under the skin | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 31-July-2028 | $845,444.86 |
| Identification of novel targets to increase human beta cell proliferation | The Regents of the University of California, San Francisco | Gregory Ku | Cures | 01-December-2020 to 31-August-2026 | $975,000.00 |
| Creation of a single-cell derived shared autoimmune framework for the study of SLE, T1D, and MS | The Regents of the University of California, San Francisco | Gabriela Fragiadakis | Cures | 01-September-2026 to 31-August-2027 | $150,000.00 |
| Sparing ER stressed human beta cells with novel kinase inhibitors of the unfolded protein response (UPR) | The Regents of the University of California, San Francisco | Feroz Papa | Cures | 01-August-2023 to 31-July-2027 | $960,000.00 |